🔗 Share this article TikTok Content Creators Driving Unofficial Trade for Unlicensed Weight-Loss Drug An underground economy for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on communication apps, based on recent findings. Investigational Drug Gaining Traction Via Social Media The experimental drug, which remains in research studies, is being advertised by online personalities for its alleged weight-reducing properties. Followers are urged to contact these accounts directly for source information, while also obtaining promotional offers. Active Trade on Messaging Platforms Separately, a flourishing trade exists on messaging services, where communities with thousands of participants share “before and after” photos, administration instructions and claims of rapid UK delivery. Sellers market the substance there before redirecting customers to WhatsApp for purchases. Learning About The Experimental Drug Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could help patients lose up to 25% of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the next Ozempic. Healthcare Professionals Voice Worries Nevertheless, doctors and pharmacists have cautions that the distribution of what is still an unapproved drug in the UK is worrisome and could result in users administering substances of uncertain source. Some professionals said the demand for retatrutide could be linked to the rising price of licensed slimming treatments such as Mounjaro. Legal Status and Implementation Selling the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unapproved drug that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012. Several influencers attempt to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still breach medicines, marketing, and consumer regulations, potentially leading to penalties, legal action or prison. Platform Reaction and Content Removal Based on the social media company, the service has removed problematic material and prohibited associated keywords and search suggestions. The organization said it was dedicated to maintaining the platform safe and allocating resources in enhancing enforcement strategies. Online Trading Operations Investigations also discovered communities with up to 9,000 participants selling retatrutide using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” immediately brings up groups with numerous of users, filled with photos of slimming results, glowing reviews and detailed instructions for preparing or injecting at residence. Within minutes of joining one group, a seller shared contact information, where most transactions occur. The vendor provided an guidebook and guaranteed shipping within 48 hours. When asked whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a image of a alleged testing documentation. Not one asked about weight, medical conditions or past usage. Item Details and Costs Inside these groups, posts display black plastic packages with Royal Mail labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.” Customers can choose between powder vials, mixed at home with sterile water, or pre-filled pens typically sold at £160 for 20mg. When asked how much time a pen should last, sellers give conflicting responses ranging from a several days to “depends on your body”. Service Moderation and Security Actions A spokesperson for the messaging service said it regularly moderated dangerous content on its service including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”. Medical Professional Warnings “People are administering substances they can’t verify. Even if the science behind this drug is valid, these digital products may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at a pharmacy service. Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to current price rises for authorized weight-loss drugs such as Mounjaro. “With costs rising, patients are using social media. But counterfeit injections are extremely risky. You can’t be certain what’s contained or whether the conditions they were made in was clean,” she said. Her staff has previously encountered patients harmed by personal administration from unconfirmed suppliers. “We understand the disappointment, but buying from messaging apps or communication platforms is taking chances with your well-being,” stated Wyllie. “These materials could be contaminated or incorrectly dosed.” Manufacturer Position A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any government authority anywhere in the world. “Consequently at this time no one can sell [it] for personal consumption,” they said, adding that any item “falsely representing itself as a company investigational product not yet approved … may subject patients to potentially serious health risks”.